Floatz logo

Targomirs

Malignant Pleural Mesothelioma

Asbestos Diseases Research FoundationPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the Malignant Pleural Mesothelioma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
AstraZeneca
Phase 2BB
Carboplatin
AstraZeneca
Phase 2BB
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 2B
Pembrolizumab
NuCana plc
Phase 2B
Atezolizumab
Swiss Cancer Institute
Phase 2B

View all 50 →

Same molecule, other indications

Targomirs is also rated in:

non-small cell lung carcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →